Underarm Sweating: Why I Will NOT Do miraDry After Reading FDA Adverse Event Reports

Underarm sweating can be miserable. It ruins clothes, creates social anxiety and makes people feel like they have to plan their day around deodorant, dark shirts and constant self-consciousness. That is exactly why miraDry sounds so tempting. It is marketed as a way to permanently reduce underarm sweating by using microwave energy to target sweat glands in the armpit. On paper, that sounds like the kind of fast fix people with underarm sweating have been waiting for.

But after reading the FDA adverse event reports, the manufacturer’s own risk information and published case reports in the medical literature, I would not do miraDry. Not for underarm sweating. Not for odour. Not for convenience. Not for the promise of “one-and-done” treatment. The reason is simple: when a treatment for underarm sweating carries documented reports of nerve symptoms, serious burns, prolonged pain, limited arm movement, inflammatory nodules, skin discolouration and even frightening cancer-related surveillance reports, my risk tolerance disappears.

Before going through the cases, one point matters. FDA MAUDE reports are safety reports, not courtroom proof. A MAUDE entry does not automatically prove that the device caused the event. These reports can be incomplete, unverified, or missing clinical details. They are signals, not final verdicts. But that does not make them irrelevant. It makes them important. They show what kinds of serious problems have been serious enough for patients, clinics, or manufacturers to report to the FDA. For me, that is enough reason to take them seriously when deciding whether I would ever use miraDry for underarm sweating.

 

FDA Report #1: Numbness, Pain, Limited Mobility and Ongoing Sweating Nine Months Later

The first report is the kind that immediately stops me in my tracks. The patient said that nine months after treatment, they still had “numbness, mobility issues, pain and excessive sweating.” That sentence alone says a lot. It describes a person who went in hoping to improve underarm sweating and, nearly a year later, was still dealing with sensory problems, movement problems, pain and continued sweating.

Start with the numbness. Temporary numbness for a few hours after a numbing injection is one thing. Numbness that lasts for months is a very different issue. To the public, numbness can sound minor, but it can signal nerve irritation, nerve compression, or nerve injury. It can mean reduced feeling in the skin, abnormal sensation, tingling, burning, or a strange, disconnected feeling in the upper arm, forearm, hand, or fingers. When a treatment is being done in the armpit, that matters because the underarm is not an empty space. It is an anatomically crowded area near important nerves, blood vessels, lymphatic structures, fat, hair follicles and sweat glands. If heat reaches deeper than intended, or if tissue geometry is not what the operator expected, the consequences are not cosmetic. They are neurologic.

Then there are the “mobility issues.” That phrase may sound vague, but in real life, it can be deeply disabling. It can mean pain with raising the arm overhead, stiffness, pulling in the underarm, weakness, reduced shoulder range of motion, or fear of moving because movement triggers pain.

The reason this matters in a miraDry discussion is that the company’s own materials already acknowledge risks such as arm pain, altered sensation, tight banding and bumps under the skin that can last months. Published case reports go further and describe brachial plexus injuries, persistent weakness and scar-like tightening that limits arm movement. So when a patient says they have had mobility problems for nine months, I do not hear a trivial complaint. I hear a life disruption.

The pain part matters just as much. Post-procedure soreness for a few days is expected with many treatments. Pain still present nine months later is not the same category of side effect. Chronic pain can be inflammatory, meaning the tissue stays irritated and tender. It can also be neuropathic, meaning the nerve itself may be irritated or injured, leading to burning, electrical, stabbing, or radiating discomfort. That distinction matters because chronic nerve-related pain can be emotionally exhausting, hard to treat and slow to recover from.

And then there is the last insult in the report: “excessive sweating.” In other words, the patient may have taken the risk and still not gotten the relief they wanted. Whether that line reflects persistent original sweating, incomplete treatment response, or another sweating pattern, the basic public takeaway is the same. This person did not simply get a less-than-perfect cosmetic result. They reported disability-level harm and did not feel their core problem had truly been solved.

What makes this report even worse from a trust standpoint is the patient’s description of the response afterwards. They said miraDry told them results were not guaranteed and told them to contact their medical provider. The provider reportedly did not offer a remedy and instead recommended a second treatment. For me, that is not reassuring. If I already had numbness, pain, mobility limitation and ongoing underarm sweating after the first session, the idea of repeating the same treatment would not feel like a solution. It would feel like doubling down on uncertainty.

FDA Report #2: A Reported Breast Cancer Case and Axillary Lymph Node Involvement

The second FDA report is the most sensitive and the one that must be discussed carefully. The reporter asked the FDA to investigate a “possible connection” after developing “breast cancer in my left breast and axillary lymph nodes” following three miraDry treatments between 2015 and 2017. This is the kind of report that demands precision because it would be irresponsible to turn a safety report into a proven claim.

So let me be clear. This report does not prove that miraDry caused breast cancer. It does not establish a biological mechanism. It does not show a device malfunction. It does not prove the timing was anything more than a coincidence. Breast cancer can develop for many reasons and the report itself contains contradictory wording about family history, which is a reminder that MAUDE reports can be imperfect. That is exactly why MAUDE is a signal-detection system and not a causation database.

But even with that caution, this report still matters. Why? Because it records a real patient who was sufficiently alarmed by the sequence of events to file a serious injury report with the FDA. From a public point of view, the reason this is frightening is anatomical proximity. The axilla, or armpit, sits right next to breast tissue and contains axillary lymph nodes, which are part of the drainage pathway for the breast and nearby tissues. When a patient later develops breast cancer and axillary lymph node involvement after repeated energy-based treatment in that same general area, it is understandable that they would want the event documented and investigated.

The “axillary lymph nodes” part is especially important for the public to understand. Lymph nodes in the armpit are not random lumps. They are immune system filters that drain the breast and surrounding tissues. They can enlarge from infection, inflammation, or cancer. In breast cancer, involvement of axillary lymph nodes often matters for staging and treatment decisions. So when a report mentions both a breast cancer diagnosis and axillary lymph node disease, that is not casual wording. It signals a medically serious situation.

This is one of the reasons I do not like how energy-based treatments are sometimes sold in overly casual language. People hear “noninvasive” and imagine “low stakes.” Those are not the same thing. A procedure can be noninvasive in the sense that it does not involve large incisions and still be high stakes because it introduces controlled thermal injury into a complicated anatomic area. Again, I am not saying this report proves causation. I am saying it was serious enough to be logged as a life-threatening, disability-level event in the FDA system and that alone is enough for me to be cautious.

For anyone reading this because they struggle with underarm sweating, this case should not be used to claim that miraDry causes breast cancer. That would go beyond the evidence. But it should absolutely be used to remind patients that post-market surveillance exists for a reason. Unexpected, severe, or frightening events need to be recorded, not brushed away simply because a treatment is marketed as routine. I would rather live with underarm sweating a little longer than ignore a report like this and pretend it means nothing.

FDA Report #3: Third-Degree Burn, Paresthesia and Upper-Arm Pain

The third FDA report is the one that most directly confirms my fear of thermal injury. It describes a patient who developed a “3rd degree burn” and had “paresthesia and pain on left upper arm.” This was not coded as a simple mild side effect. It was filed as a serious injury.

A third-degree burn is not a small cosmetic issue. It is a full-thickness burn, meaning the damage extends through the full depth of the skin and can involve destruction of nerve endings, sweat glands, hair follicles and deeper tissues. People sometimes assume a burn always looks dramatic immediately, but deep burns can evolve, declare themselves over time and leave behind scarring, tissue loss, contour change, contracture and chronic pain. In some cases, the burned area may even feel less pain at the centre because nerve endings have been destroyed, while the surrounding tissues remain very painful. So when I read “3rd degree burn” in connection with a treatment for underarm sweating, I do not see a routine post-procedure issue. I see a serious wound.

The report also mentions paresthesia. That word means abnormal sensation: tingling, pins and needles, prickling, crawling, or numbness. In public language, it often means the nerves are irritated or not functioning normally. When paresthesia is paired with upper-arm pain after an armpit microwave treatment, it raises the obvious concern that the heat or surrounding inflammation affected nearby nerves.

One of the most revealing parts of this report is the manufacturer’s narrative. The company said its review of the device history and treatment data did not show unusual device performance. Instead, the manufacturer suspected that the clinic may have treated the same area twice in one session, sometimes called a double-pass, or may not have used the recommended anaesthesia volume. The report also explains that the anaesthesia technique is not just about comfort. The volume and placement of fluid can help create separation between skin and deeper nerves, which may reduce the risk of nerve injury. That is a crucial point for the public: this is not a plug-and-play beauty treatment. The safety of the procedure appears to depend heavily on anatomy, proper training, precise placement, correct timing, correct cooling, correct lubricant and not re-treating the same site.

To me, that is not comforting. It actually makes the treatment less attractive. If a clinic’s depth judgment, pass pattern, cooling performance, anaesthesia technique, or site overlap can be the difference between a routine outcome and a full-thickness burn, then the treatment is more operator-dependent than many patients probably realise. And the company’s own manual reinforces that concern. It warns against treating the same skin site multiple times in one session, warns that burns of first, second, or third degree are possible and warns that using the wrong lubricant can reduce surface cooling and lead to blisters or burns.

There is another detail in this report that matters: the burn was described 4.1 months after treatment. To me, that suggests the injury was recognised or documented months later, not that a completely normal underarm suddenly became burned from nothing after four months. Deep thermal injuries can take time to fully declare themselves and delayed presentation does not make them less serious. If anything, it shows how long the shadow of one underarm sweating procedure can last.

What These Cases Mean for Anyone Considering miraDry for Underarm Sweating

Taken together, these three FDA reports tell a story that I cannot ignore. They do not prove that every bad outcome was directly caused by miraDry. But they do show the spectrum of harms that have been serious enough to reach federal post-market surveillance: prolonged numbness, pain, limited mobility, persistent sweating, a reported cancer-related event involving axillary lymph nodes and a third-degree burn with arm symptoms.

These reports also line up with what is already acknowledged elsewhere. The current miraDry user manual lists altered sensation, arm pain, weakness, hyperpigmentation, lumps under the skin, tight banding, infection or abscess and burns up to third degree as possible risks. In one clinical study summarized in the manual, 61% of subjects had at least one treatment-related adverse event, with numbness or tingling in a treatment limb reported in 39%.

In another study in the same manual, all subjects had at least one treatment-related adverse event and common effects included lumps under the skin, numbness or tingling, swelling and tenderness. Published case reports add descriptions of bilateral brachial plexus injury, unilateral median nerve plexopathy, inflammatory nodules and scarring that mimicked hidradenitis suppurativa and deep-burn-like complications with retractile scar bands and painful restriction of arm movement.

That is why my four original objections to miraDry for underarm sweating have only gotten stronger.

First, the nerve-damage issue is real. I cannot verify a universal FDA-backed “1% nerve damage” figure, so I am not going to present that number as a settled fact. But I can say that nerve-related symptoms and nerve injuries are documented across FDA reports, the manufacturer’s own warnings and published case reports. If the best defence of the treatment is that nerve injury is rare, that still does not make it acceptable to me. Rare is not the same thing as impossible and nerve injuries are not minor when they happen.

Second, my concern about PIH is not theoretical. The manual itself lists hyperpigmentation in the treatment area. Post-inflammatory hyperpigmentation happens when the skin responds to injury or inflammation by producing or distributing pigment unevenly, leaving behind darkened patches. Underarms are a terrible place for this if you are already self-conscious. They are warm, friction-prone and often shaved. I cannot honestly say the FDA reports prove that local anaesthetic “heating up” directly causes PIH. The stronger, more defensible point is that this is a heat-based procedure in a sensitive area, pigment change is already acknowledged as a possible side effect and any treatment that triggers significant inflammation can leave lasting discolouration.

Third, burns are clearly documented. This is not a rumour or a one-off forum story. The manufacturer says burns of first, second, or third degree are possible. The FDA has a report of a third-degree burn. Another published case report describes complications that resembled deep axillary burns, with dermal detachment, subcutaneous collections, dermal thickening, retractile scars, pain and sharply limited arm abduction. For a treatment marketed to people bothered by underarm sweating, that risk is simply not acceptable to me.

Fourth, the “granuloma” concern is best described more precisely as inflammatory nodules, fibrosis, abscesses, dermal thickening and scar-forming inflammation. I have not seen evidence strong enough to claim that the anaesthetic solution itself heats up and creates proven granulomas as an established mechanism. What I have seen are reports and case papers describing painful nodules, hidradenitis-like scarring, abscesses, chronic inflammation, thickening of tissue and retractile bands that limit movement. In practical terms, that is more than enough for me to say no. I do not want to trade underarm sweating for underarm pain, lumpiness, scarring, or months of restricted motion.

My Final Verdict on miraDry for Underarm Sweating

I understand the appeal of miraDry. Underarm sweating can wear people down. But after reading these FDA reports and the supporting medical literature, I would not do it. Not because I think every patient will be harmed. Not because I think every report proves causation. And not because I think nobody ever gets a good result. I would not do it because the downside profile is too serious for me, too dependent on perfect technique and too permanent in the wrong way if something goes badly.

If I were treating my own underarm sweating, I would much rather start with options that are more conservative or more reversible, such as Deep Radiofrequency to shrink the sweat glands, stronger antiperspirants, topical glycopyrronium products when appropriate, or botulinum toxin injections. Those approaches are not perfect, but they do not ask me to accept microwave injury in an anatomically delicate area with documented reports of nerve problems, pigment change, burns, prolonged pain, inflammatory nodules and treatment failure.

For me, that is the real conclusion. Underarm sweating is frustrating. But a bad outcome from miraDry could be far worse.

References

1. FDA. About Manufacturer and User Facility Device Experience (MAUDE) Database; description and limitations of MDR reports. 
2. FDA MAUDE Adverse Event Report, MDR Report Key 10372703: patient-reported numbness, pain, mobility issues, continued sweating, serious injury/disability. 
3. FDA MAUDE Adverse Event Report, MDR Report Key 9192096: reported possible connection with breast cancer and axillary lymph nodes, serious injury/life-threatening/disability coding. 
4. FDA MAUDE Adverse Event Report, MDR Report Key 9572126: third-degree burn, paresthesia, upper-arm pain and manufacturer narrative on suspected technique issues. 
5. miraDry MD4000-MC User Manual: indications, listed risks, thin-patient nerve warning, same-site treatment warning, anesthesia and cooling/lubricant precautions and clinical adverse-event summaries. 
6. Puffer RC, Bishop AT, Spinner RJ, Shin AY. Bilateral Brachial Plexus Injury After MiraDry Procedure for Axillary Hyperhidrosis. PubMed abstract. 
7. Lee FG, Kochuba AL, Shen JK, et al. Conservative Management of Median Nerve Brachial Plexopathy after Microwave-based MiraDry Treatment for Axillary Hyperhidrosis. PMC full text. 
8. Bayoux R, Barani C, Curings P, et al. Complications Following Treatment for Excessive Axillary Sweating With Microwaves: A Case Report. PubMed and PMC full text. 
9. Aleisa A, Feingold DS. Development of Inflammatory Nodules and Scarring Mimicking Hidradenitis Suppurativa after Treatment of Axillary Hyperhidrosis Using a Microwave-based Energy Device. PubMed. 
10. National Cancer Institute and Mayo Clinic background on axillary lymph nodes and swollen lymph nodes. 
11. MedlinePlus and Cleveland Clinic background on third-degree burns, numbness and paresthesia. 
12. StatPearls overview of post-inflammatory hyperpigmentation. 
13. Mayo Clinic, American Academy of Dermatology and MedlinePlus treatment overviews for hyperhidrosis and underarm sweating alternatives.